Pyridoxamine for the Treatment of Diabetic Kidney Disease
OwnerThorsten Degenhardt, Robert Schotzinger +1inventors
InventorsThorsten Degenhardt, Robert Schotzinger, J. Wesley Fox
Life of this patent
Estimating the term…
Abstract
The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
Claims17
A pharmaceutical composition comprising:
- (a) a dosage unit of 50 mg to 500 mg of pyridoxamine, or a pharmaceutically acceptable salt thereof;
- and
- (b) a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising:
- (a) pyridoxamine, or a pharmaceutically acceptable salt thereof;
- and
- (b) one or more compounds selected from the group consisting of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldose reductase inhibitors, calcium blockers, diuretics, glycosaminoglycans, insulin, incretin mimetics, insulin sensitizers, statins, fibrates, glucose uptake inhibitors, sulfonylureas, superoxide dismutase (SOD) and SOD mimetics, thiamine pyrophosphate and prodrugs thereof, transketolase inhibitors, AGE inhibitors, and protein kinase C inhibitors.
A method for limiting the progression of renal disease and/or diabetic complications in a human diabetic patient being treated with one or more therapeutics selected from the group consisting of antihypertensive medications and glycemic control agents, comprising administering to the human diabetic patient an amount of pyridoxamine, or a pharmaceutically acceptable salt thereof, effective to limit the progression of renal disease and/or diabetic complications in the diabetic human patient.
A method for limiting the progression of renal disease and/or diabetic complications in a human diabetic patient comprising administering to a human diabetic patient with a baseline serum creatinine concentration of greater than or equal to 1.3 mg/dL an amount of pyridoxamine, or a pharmaceutically acceptable salt thereof, effective to limit the progression of renal disease and/or diabetic complications in the human diabetic patient.
A method for limiting the progression of renal disease and/or diabetic complications in a human diabetic patient, comprising administering to a human diabetic patient with a whole blood HbA1C level of greater than 6.5% an amount of pyridoxamine, or a pharmaceutically acceptable salt thereof, effective to limit the progression of renal disease and/or diabetic complications in the human diabetic patient.
Dependencies are inferred from the claim text.